35986841_10216840653711318_1105697261150535680_n

Design of novel potential protease inhibitors for the treatment of HIV // GP // Dr. Rana Hosny Refaey (2018 - 2019) (Record no. 24936)

MARC details
000 -LEADER
fixed length control field 02334nam a22002657a 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20190720122141.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 190709b xxu||||| |||| 00| 0 eng d
040 ## - CATALOGING SOURCE
Transcribing agency MSA
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Ramla Ahmed Ali 152887
245 ## - TITLE STATEMENT
Title Design of novel potential protease inhibitors for the treatment of HIV // GP // Dr. Rana Hosny Refaey (2018 - 2019)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Giza :
Name of publisher, distributor, etc. MSA,
Date of publication, distribution, etc. 2019.
300 ## - PHYSICAL DESCRIPTION
Extent 65 p.
440 ## - SERIES STATEMENT/ADDED ENTRY--TITLE
Title Pharmacy distinguished Projects 2019
500 ## - GENERAL NOTE
General note Pharmacy - Pharmaceutical Chemistry <br/>
520 ## - SUMMARY, ETC.
Summary, etc. Human immunodeficiency virus (HIV) is a serious infection that progressively destructs the human immune system. Protease enzyme is a very important enzyme in the life cycle of the HIV and its replication. The Protease inhibitors are classified as one of the important classes in HIV treatment as they decrease the protease enzyme of the HIV. However, they have shown a risk in causing insulin resistance and leading to diabetes mellites due to their high affinity to GLUT4. Consequently, we tried to design novel protease inhibitors that <br/>have reduced affinity to GLUT4 and exhibit low incidence of insulin resistance. For such <br/>design to be developed, computer-based drug design methods were used. Using MOE program, the protease enzyme was primarily docked in itself for validation and then protease inhibitors were docked in it to observe the energy values and interactions. Then, protease inhibitors were docked in GLUT4 homology model -created on SwissModel- to <br/>explore their interactions with it and to identify interactions responsible for binding to GLUT4 causing insulin resistance. For the lead optimization step Darunavir and Ritonavir were chosen. In Darunavir, N38 was changed into C38 and a pentane ring was attached to 018. For Ritonavir, the N5 was changed to $5. These changes lead to significant variation in the affinity of the drugs to both protease enzyme and GLUT4, increasing the affinity to protease enzyme and decreasing it to GLUT4.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Human immunodeficiency virus
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element potential protease
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Pharmaceutical Chemistry
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Aya Mohamed Ahmed 150869
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Lamiaa Khaled Farouk 150973
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Nada Ibrahim El-Sayed 150131
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://qrgo.page.link/xhK2h">https://qrgo.page.link/xhK2h</a>
Public note FULL TEXT PRESS HERE
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme Dewey Decimal Classification
Koha item type Distinguished Graduation Projects
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
    Dewey Decimal Classification     Centeral Library Centeral Library Soft Copy located on library Cataloge 09.07.2019   GP38PH2019-Pharm.chem 82019 09.07.2019 09.07.2019 Distinguished Graduation Projects